Not a good buy right now for an impatient entry: price is pressing into near-term resistance (~103.2–104.6) with short-term momentum looking stretched (RSI6 ~70.6).
No Intellectia “strong-buy” timing help today (no AI Stock Picker / no SwingMax), so there’s no edge suggesting you must buy this pre-market.
Options positioning is mildly bullish (more calls than puts), but elevated IV suggests the market is pricing in uncertainty; combined with heavy insider selling, risk/reward for an immediate chase is not attractive.
If you must take action today: hold/avoid initiating at ~103–104; the cleaner buy zone is closer to ~101 (pivot) or below, where support is stronger.
Technical Analysis
Trend/Momentum: MACD histogram is positive and expanding (bullish momentum), but RSI6 at ~70.6 signals the move is getting stretched short-term.
Moving averages: converging MAs suggests a transition zone rather than a clean trend; breakouts can fail more often in this regime.
Key levels: Pivot ~100.93 (important support/decision point). Resistance: R1 ~103.20 (already being tested/cleared pre-market) and R2 ~104.60 (next upside cap).
Probabilistic pattern read: similar-pattern stats imply slightly negative skew near-term (next day ~-1.14%, next month ~-1.18%), arguing against chasing strength.
Activity: today’s options volume is ~168.6% of the 30-day average → elevated attention/positioning.
Volatility: IV30 ~26% vs historical vol ~19.6% with IV percentile ~77 → options look expensive; market is assigning above-normal uncertainty/risk premium.
Interpretation: bullish positioning exists, but the high IV + price near resistance makes “buy now” less compelling for immediate upside without a pullback.
Technical Summary
Sell
6
Buy
8
Positive Catalysts
with large projected cost synergies ($2.1B cited) can support longer-horizon sentiment.
Neutral/Negative Catalysts
Insider activity: insiders are selling and the selling amount jumped sharply recently (+1990% last month) → negative near-term signal.
Deal/overhang risk: “Kenvue overhang” cited by UBS; integration and execution risk can cap multiple expansion.
Macro/headwinds: analysts cite potential oil and FX headwinds into 2026; sector fundamentals/volume growth concerns persist.
Positioning risk: price is trading into resistance with short-term momentum stretched, raising the odds of a fade/pullback.
Profitability: Net income $499M, +11.63% YoY; EPS $1.50, +11.94% YoY (earnings growth driven despite lower revenue).
Margins: Gross margin 35.91%, +1.53% YoY (supports the cost/transformation narrative).
Read-through: quality/defensive characteristics remain, but growth is mixed (earnings up, revenue down), which often limits near-term upside without a clear catalyst.
Political/congress check:
Congress trading (90 days): no data available.
Politicians/influential figures: no reported recent activity in the provided data.
Hedge funds: neutral; no significant recent trend.
Wall Street cons: sector multiple compression, volume growth challenges, FX/commodity headwinds, and deal-related overhang/integration risk.
Wall Street analysts forecast KMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMB is 127.71 USD with a low forecast of 95 USD and a high forecast of 162 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast KMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMB is 127.71 USD with a low forecast of 95 USD and a high forecast of 162 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
8 Hold
1 Sell
Moderate Buy
Current: 104.260
Low
95
Averages
127.71
High
162
Current: 104.260
Low
95
Averages
127.71
High
162
UBS
Peter Grom
Neutral
maintain
$107 -> $110
AI Analysis
2026-01-28
Reason
UBS
Peter Grom
Price Target
$107 -> $110
AI Analysis
2026-01-28
maintain
Neutral
Reason
UBS analyst Peter Grom raised the firm's price target on Kimberly-Clark (KMB) to $110 from $107 and keeps a Neutral rating on the shares. While the underlying business is solid, the Kenvue (KVUE) overhang should persist, the analyst tells investors in a research note.
BofA
Anna Lizzul
Buy
downgrade
$148 -> $130
2026-01-28
Reason
BofA
Anna Lizzul
Price Target
$148 -> $130
2026-01-28
downgrade
Buy
Reason
BofA analyst Anna Lizzul lowered the firm's price target on Kimberly-Clark to $130 from $148 and keeps a Buy rating on the shares. The firm sees Kimberly-Clark executing on its transformation, but lowers its price target on a lower P/E multiple applied to its 2027 EPS estimate due to multiple compression in the space, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMB
